ARDX
Ardelyx is a commercial-stage biopharmaceutical company that develops and sells medicines based on tenapanor, a first-in-class oral small molecule that inhibits a sodium/hydrogen exchanger (NHE3) in the intestines. The company currently markets two approved tenapanor products: IBSRELA for irritable bowel syndrome with constipation and XPHOZAH for managing phosphorus levels in dialysis patients, while also running a Phase 3 trial to expand IBSRELA's use to chronic idiopathic constipation and developing a next-generation NHE3 inhibitor for multiple therapeutic areas.
Pipeline
Tenapanor is a locally acting inhibitor of the sodium/hydrogen exchanger 3 (NHE3), an antiporter expressed on the apical surface of the small intestine and colon primarily responsible for the absorption of dietary sodium.